B. Ley, H. R. Collard, T. E. King, and J. , Clinical course and prediction of survival in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, vol.183, pp.431-440, 2011.

G. Raghu, M. Remy-jardin, J. L. Myers, L. Richeldi, C. J. Ryerson et al., Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, Am J Respir Crit Care Med, vol.198, pp.44-68, 2018.

P. W. Noble, C. Albera, W. Z. Bradford, U. Costabel, M. K. Glassberg et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet, vol.377, pp.1760-1769, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00873255

T. E. King, W. Z. Bradford, S. Castro-bernardini, E. A. Fagan, I. Glaspole et al., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2083-2092, 2014.

C. Albera, U. Costabel, E. A. Fagan, M. K. Glassberg, E. Gorina et al., Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function, Eur Respir J, vol.48, pp.843-851, 2016.

L. Richeldi, V. Cottin, R. M. Du-bois, M. Selman, T. Kimura et al., Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials, Respir Med, vol.113, pp.74-79, 2016.

U. Costabel, Y. Inoue, L. Richeldi, H. R. Collard, I. Tschoepe et al., Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis Across Prespecified Subgroups in INPULSIS, Am J Respir Crit Care Med, vol.193, pp.178-185, 2016.

T. M. Maher, J. J. Swigris, M. Kreuter, M. Wijsenbeek, N. Cassidy et al., Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views, Respiration, pp.1-11, 2018.

U. Costabel, C. Albera, L. H. Lancaster, C. Y. Lin, P. Hormel et al., An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP), Respiration, vol.94, pp.408-415, 2017.

P. W. Noble, C. Albera, K. U. Kirchgaessler, F. Gilberg, U. Petzinger et al., Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment

, Eur Respir J, vol.48, p.1809, 2016.

P. W. Noble, C. Albera, W. Z. Bradford, U. Costabel, R. M. Du-bois et al., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials, Eur Respir J, vol.47, pp.243-253, 2016.